RESEARCHER PROFILE
Professor Divya Mehta, Principal Research Fellow
Stress Genomics Laboratory, School of Biomedical Sciences
QUT (Queensland University of Technology), Australia
Understanding the interaction between genes and lifestyle factors in response to stress can lead to potential therapeutic interventions for stress-related disorders. This research is crucial for promoting health and well-being.
Professor Divya Mehta works as a Principal Research Fellow at the Stress Genomics Laboratory, in QUT (Queensland University of Technology) in Australia, specialising in stress genomics and mental health. Her education started in the UK with undergraduate and Masters, followed by her PhD in Germany and postdoctoral at Max Planck Institute of Psychiatry. 11 years ago Professor Mehta moved to Australia.
Her focus is research is understanding how genes and lifestyle factors interact to drive our response to stress, particularly in emergency responders, veterans, and elite athletes, with a focus on epigenetics.
Epigenetics are the dynamic part of our DNA, that change across our lifetime in response to stress, exercise, social support, and nutrition, impacting our overall health.
Social support can reduce and reverse negative impacts of stress on genes, leading to potential therapeutic interventions for stress-related disorders.
Research at the intersection of statistics, genomics, and mental health can provide valuable insights into the devastating impact of mental health disorders on individuals, families, and communities.
Professor Mehta has recently commenced research into elite athlete physical and mental health impact performance, with research at the intersection of statistics, genomics, and mental health. This research is ahead of, and in anticipation of, the Summer Olympics in Brisbane in 2032.
Understanding the drivers of health and well-being is crucial for ensuring a happy and healthy life, which is Professor Mehta’s passion. Outside of the work environment, she also enjoys sports, volunteering for animal rescue, and spending time with family.
-
World-first clinical trial improves patient outcomes for kidney transplants (2023)
A world-first clinical trial conducted at the Royal Adelaide Hospital (RAH) and at hospitals across Australia and New Zealand has identified the best fluid treatment to reduce the risk of patients requiring dialysis after a kidney transplant.
Around one in three people who receive a kidney transplant suffer delayed graft function, which means the transplant doesn’t work immediately and they require dialysis.
The lead-author of the study, was Royal Adelaide Hospital Nephrologist and University of Adelaide researcher, Dr Michael Collins.
-
Investigating the benefits of donor human milk for preterm infants
Together, SAHMRI and Lifeblood are leading a consortium to revolutionise the way human milk, and novel products made from human milk, are used as nutritional and medical interventions to improve health outcomes in vulnerable infants, but with potential application for a diverse range of medical indications.
Currently, babies who are born early preterm – before 32 weeks – are given donor milk when their own mother’s milk is not available or in short supply. Whether donor milk is beneficial for babies born just a few weeks early is unclear, as very little research has been undertaken with these babies.
The GIFT Trial will soon commence as an investigation between SAHMRI, the University of Adelaide, the Red Cross Lifeblood Milk Bank conducted at five sites across three states in Australia.
-
Dr Paul Griffin
MATER HEALTH SERVICES, QUEENSLAND, AUSTRALIA
